MK-677 With Food or Supplements: What Has Actually Been Tested

Meal Advice Requires a Meal Experiment

The legacy page assigned carbohydrate, calcium, arginine, GABA, and melatonin effects, then converted them into timing instructions. It did not identify a fed-versus-fasted ibutamoren pharmacokinetic study that measured those claims.

FDA's May 2026 food-effect guidance explains why study design matters:

“well-conducted FE studies can inform how, when, and why drugs should or should not be administered with food.”

The issuer is FDA's Office of Clinical Pharmacology within the Center for Drug Evaluation and Research. The excerpt describes the evidence needed for oral-drug food instructions; it is not an ibutamoren finding or endorsement.

Figure 1

What a definitive FDA-style food-effect study does, and what exists for ibutamoren

Text version of this diagram

1. Design: Randomized, single-dose, two-period crossover: the same people take the product once fasted and once fed.
2. Fasted arm: After an overnight fast of at least 10 hours, the dose is taken with 240 mL (8 fluid ounces) of water.
3. Fed arm: After the same fast, a high-fat meal is started 30 minutes before the dose and eaten in 30 minutes or less.
4. Test meal: 800 to 1000 calories, with about 50 percent of calories from fat.
5. Ibutamoren today: FDA's review found only brief human pharmacokinetic descriptions and no additional PK data. No fed-versus-fasted comparison exists to set a meal or spacing rule.

The Interaction-Evidence Map

What FDA Found About Ibutamoren Pharmacokinetics

FDA's 2024 compounding review found that submitted sources described ibutamoren as orally active and long-acting but did not provide a detailed PK profile. The review states that FDA did not identify additional PK data in its literature search (PDF pages 37–38).

That absence matters because a meal instruction normally depends on comparisons such as:

• exposure under fed versus fasted conditions;
• peak concentration and total exposure;
• the exact formulation tested;
• meal fat and calorie content;
• timing between food and administration; and
• whether any measured exposure change affects benefit or harm.

Without those inputs, “take with food,” “take fasting,” and “separate by two hours” are different guesses, not evidence-based alternatives.

Why Existing Trial Context Does Not Answer the Food Question

Copinschi and colleagues randomized nine healthy young men to placebo and two oral MK-677 study arms, administered at bedtime for seven consecutive days (PMID 8768828; DOI 10.1210/jcem.81.8.8768828). The study measured 24-hour GH and cortisol profiles plus IGF-1 and IGFBP-3. It did not randomize fed versus fasted exposure.

Murphy and colleagues studied eight adults ages 24–39 during controlled calorie restriction and compared MK-677 with placebo (PMID 9467534; DOI 10.1210/jcem.83.2.4551). The experimental question was nitrogen balance under energy restriction—not whether a high-fat, high-carbohydrate, or calcium-containing meal changed ibutamoren absorption.

A controlled meal environment can reduce noise in a study. It does not automatically make the study a food-interaction trial.

Supplements Need Product-Specific Co-Administration Data

The absence of a reported interaction does not prove compatibility. But separate supplement physiology also cannot prove that two substances “stack,” cancel, or require a precise interval.

The berberine interaction page examines glucose-related pathway overlap without inventing a clinical interaction. The creatine page separates performance-supplement evidence from ibutamoren outcomes, while the nutrition review addresses diet context without treating food as a dosing tool.

For a direct interaction claim, the useful study would specify the ibutamoren substance and formulation, the supplement identity and amount, exposure timing, PK and pharmacodynamic measurements, and safety outcomes. None was identified for the commonly named combinations.

Formulation Can Change the Answer

Even a future food-effect finding would belong first to the formulation tested. FDA's 2024 review noted gaps in physical and chemical characterization of nominated ibutamoren mesylate bulk substance, including critical identity, purity, impurity, and residual-solvent information.

A study-formulation result cannot simply be assigned to a different compounded capsule or an online product with uncertain contents.

The Responsible Bottom Line

There is not enough product-specific PK evidence to prescribe an ibutamoren meal, fasting window, or supplement-spacing schedule. Existing studies show hormonal and metabolic effects in defined research settings; they do not supply fed-versus-fasted labeling or a compatibility matrix for common supplements.

Medical review of this revision is pending. FDA, investigators, institutions, journals, and study authors do not endorse ibutamoren, HealthRX.com, or this page.